Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | XPO1 | O14980 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584194 | 0.79 | CHRNB2 (0.61) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL344042 | 0.78 | RAB9A (0.53) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL4414873 | 0.74 | RAB9A (0.53) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL20816371 | 0.74 | RAB9A (0.53) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL4411089 | 0.74 | RAB9A (0.53) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL2210395 | 0.74 | RAB9A (0.53) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL8540443 | 0.74 | RAB9A (0.53) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL4405559 | 0.74 | RAB9A (0.53) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL4403726 | 0.74 | RAB9A (0.58) | RAB9AL3MBTL1NPC1MAPK1SMN1; SMN2 | |
| SCHEMBL2210517 | 0.72 | NPC1 (0.77) | RAB9AL3MBTL1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| US-6498180-B1 | SUCH AS 2-(3'-HYDROXYMETHYL-2'-CARBOXYCYCLOPROPYL)GLYCINE; MODULATING METABOTROPIC GLUTAMATE RECEPTOR; TREATING DISORDERS OF CENTRAL NERVOUS | ELI LILLY AND COMPANY | 2002-12-24 | — | — | US | claimed |
| EP-1189873-A1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | Lilly, S.A. (ES) | 2002-03-27 | — | — | EP | claimed |
| WO-2000075101-A1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | LILLY, S.A. (ES) | 2000-12-14 | — | — | WO | claimed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| WO-2005044008-A2 | 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-6498180-B1 | SUCH AS 2-(3'-HYDROXYMETHYL-2'-CARBOXYCYCLOPROPYL)GLYCINE; MODULATING METABOTROPIC GLUTAMATE RECEPTOR; TREATING DISORDERS OF CENTRAL NERVOUS | ELI LILLY AND COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1189873-A1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | Lilly, S.A. (ES) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000075101-A1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | LILLY, S.A. (ES) | 2000-12-14 | — | — | WO | disclosed |
| EP-0215739-B1 | SYNTHESIS OF BETA-LACTAM COMPOUNDS | CIBA-GEIGY AG (CH) | 1993-09-01 | — | — | EP | disclosed |
| US-5215997-A | Synthesis of beta-lactam compounds | CIBA-GEIGY CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| US-5153315-A | Penicilllin deriviatives | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| US-4962196-A | (3S, 4R)-3,4-trans-disubstituted azetidin-2-one intermediates | CIBA-GEIGY CORPORATION (US) | 1990-10-09 | — | — | US | disclosed |
| EP-0297042-A1 | Substituted penem compounds | CIBA-GEIGY AG (CH) | 1988-12-28 | — | — | EP | disclosed |
| EP-0233155-A1 | Aminoacyloxymethyl compounds | CIBA-GEIGY AG (CH) | 1987-08-19 | — | — | EP | disclosed |
| EP-0215739-A1 | Synthesis of beta-lactam compounds | CIBA-GEIGY AG (CH) | 1987-03-25 | — | — | EP | disclosed |
| EP-0201459-A1 | Acylaminomethyl-penem compounds, their preparation and pharmaceutical formulations containing them | CIBA-GEIGY AG (CH) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | RAB9A 20/4885L3MBTL1 2280/4885NPC1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.